What's new on ICE?
DISCLAIMER: These news articles have been reproduced verbatim as on the original site, with the exception of replacing certain terms with United Nations terminology when necessary. As such, the articles are provided for general reference purposes. Their content does not imply official endorsement or acceptance by the United Nations.
- Noviembre de 2024 - SAT de UNODC: Nueva evolución de cannabinoides “semisintéticos”
- November 2024 - UNODC EWA: New evolution of “semi-synthetic” cannabinoids
- Octubre de 2024 – SAT de UNODC: Número de NSP, informadas por primera vez, en su nivel más bajo desde 2010
- October 2024 - UNODC EWA: Number of NPS reported for the first time at lowest level since 2010
- Octubre de 2024 – SAT de UNODC: Importante diversificación entre cannabinoides sintéticos y opioides en 2023
- October 2024 – UNODC EWA: Significant diversification among synthetic cannabinoids and opioids in 2023
- Septiembre de 2024 - OMS: Siete nuevas sustancias psicoactivas y un medicamento sometidos a examen crítico por el 47º Comité de Expertos en Farmacodependencia
- September 2024 - WHO: Seven new psychoactive substances and one medicine under critical review by 47th Expert Committee on Drug Dependence
- Agosto de 2024 - SAT de UNODC: Aumenta el consumo de ketamina en el Este y Sudeste de Asia, así como en Oceanía
- August 2024 - UNODC EWA: Ketamine in East and Southeast Asia and Oceania on the rise
The IQAP International Collaborative Exercises (ICE) programme is aimed at helping drug-testing laboratories worldwide assess their own performance and take corrective actions, when appropriate. The ICE programme has two groups:
- The Seized Materials Group: The test samples in this group contain controlled drugs from actual seizures.
- Biological Specimens Group: The test samples in this group contain controlled drugs and their metabolites in freeze-dried human urine.